Prof. Dr. Ekkehard Schütz
About Prof. Dr. Ekkehard Schütz
Professional Role at Oncocyte and Chronix Biomedical
Prof. Dr. Ekkehard Schütz serves as the Chief Science Officer at Oncocyte. He joined the company in April 2021 through the acquisition of Chronix Biomedical. Alongside his role at Oncocyte, Schütz is the managing director of Chronix Biomedical GmbH, which is wholly owned by Oncocyte. Additionally, he holds the position of Chief Medical Officer for Europe within the organization.
Academic Involvement at Georg-August-University
Prof. Dr. Ekkehard Schütz engages in academic teaching at the Georg-August-University, specializing in molecular genetics and diagnostics. His early professional development included comprehensive training in laboratory medicine at the Department of Clinical Chemistry in the hospital of the Georg-August-University of Göttingen, spanning from 1989 to 2001.
Contributions to Chronix Biomedical
In 2001, Prof. Dr. Ekkehard Schütz joined Chronix Biomedical Inc. and was instrumental in establishing its German subsidiary in 2002, which functions as the company's R&D site. His leadership has significantly contributed to the development and expansion of Chronix Biomedical's German operations.
Academic and Professional Recognitions
Prof. Dr. Ekkehard Schütz was elected as a fellow of the National Academy for Clinical Biochemistry, now known as the Academy of the American Association for Clinical Chemistry (FAACC), in 2014. His extensive academic contributions include over 170 peer-reviewed publications and book chapters, along with over 100 published congress abstracts. He has also received multiple international scientific awards.
Editorial and Reviewer Roles
Prof. Dr. Ekkehard Schütz serves as a reviewer for various prestigious international scientific journals. These include the Proceedings of the National Academy of Sciences (PNAS), Clinical Chemistry (Clin Chem), Clinical Biochemistry (Clin Biochem), and Nucleic Acids Research (NAR). His expertise is sought after in the scientific community for his critical analyses and insights.